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ABSTRACT
A key challenge for the academic and biopharma-
ceutical communities is the rapid and scalable pro-
duction of recombinant proteins for supporting
downstream applications ranging from therapeutic
trials to structural genomics efforts. Here, we
describe a novel system for the production of re-
combinant mammalian proteins, including immune
receptors, cytokines and antibodies, in a human
cell line culture system, often requiring <3 weeks
to achieve stable, high-level expression: Daedalus.
The inclusion of minimized ubiquitous chromatin
opening elements in the transduction vectors is
key for preventing genomic silencing and maintain-
ing the stability of decigram levels of expression.
This system can bypass the tedious and
time-consuming steps of conventional protein pro-
duction methods by employing the secretion
pathway of serum-free adapted human suspension
cell lines, such as 293 Freestyle. Using optimized
lentiviral vectors, yields of 20–100mg/l of correctly
folded and post-translationally modified, endotoxin-
free protein of up to  70kDa in size, can be
achieved in conventional, small-scale (100ml)
culture. At these yields, most proteins can be
purified using a single size-exclusion chromatog-
raphy step, immediately appropriate for use in
structural, biophysical or therapeutic applications.
INTRODUCTION
The ability to express milligram-to-gram quantities of
highly puriﬁed, recombinant proteins has become essential
to support cutting-edge therapeutic and structural
genomics efforts. Available protein production platforms
are commonly based on expression in bacterial, yeast,
insect and, more recently, mammalian cell culture
systems. Systems based on recombinant expression in
Escherichia coli, one of the oldest and most widely used
expression platforms, allows for the simple, rapid and
cost-effective production of target proteins. However, eu-
karyotic proteins produced in bacteria often suffer from
poor solubility, resulting in aggregation or misfolding, or
lack proper post-translational modiﬁcations necessary for
full biological activity (1,2). Yeast-based expression
systems, particularly those employing Saccharomyces
cerevisiae and Pichia pastoris, offer improvements over
bacterial systems in terms of yield, the complexity of
proteins successfully expressed and the ability to
perform some (but not all) post-translational modiﬁca-
tions (3,4). Baculovirus-based or stably transformed
insect cell systems using Drosophila (S2) or Spodoptera
frugiperda (SF9) derived cell lines have become widely
used for routine production of complex recombinant
proteins. However, insect cell line-based platforms can
be cumbersome to implement and do not correctly recap-
itulate complex mammalian N-glycans containing galact-
ose or sialic acid residues (5,6).
For these reasons, most recombinant proteins for bio-
medical use have been produced in mammalian cell lines,
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onic kidney (HEK) lines. Up to 70% of the recombinant
proteins produced commercially are made in CHO cells,
including many successful therapeutic biologics (e.g.
Etanercept, Trastuzumab and Rituximab) (7). However,
CHO-based expression systems may not be ideal for thera-
peutic protein production due to the addition of terminal
galactose-a-1,3-galactose epitopes during N-glycosylation
of recombinant glycoproteins. This antigen can be respon-
sible for allergic hypersensitivities leading to adverse
clinical events such as anaphylaxis, as seen in the use of
the anti-cancer antibody Cetuximab (8). Another major
drawback of using mammalian cell line-based platforms
is the frequent need to laboriously select stable, high ex-
pressing clones which can be tedious, time consuming
(often taking months) and costly.
Puriﬁcation of cytoplasmically targeted recombinant
proteins requires cell lysis after culturing to high densities,
an inherently piecemeal approach. However, stable trans-
duction of recombinant proteins targeted to the secretion
pathway generates producer lines that can be consistently
maintained in culture, allowing the protein to be harvested
periodically and puriﬁed directly from culture super-
natants over a period of time. Secretion may also
improve the expression of proteins that are toxic to the
producer line when produced as cytoplasmically targeted
constructs. Recent advances in developing cell lines
adapted to serum-free media synergizes with this
approach by minimizing serum protein contaminants, dra-
matically simplifying puriﬁcation. Indeed, most
recombinantly expressed therapeutic proteins, such as
cytokines and antibodies, are secreted proteins in their
native state.
Introduction of vectors encoding recombinant protein
constructs for large-scale protein production in transient
expression systems is often accomplished with costly and
sometimes unreliable chemical transfection reagents.
Alternatively, lentiviral vectors can be used to efﬁciently
transduce cells yielding stable transductants (9,10).
However, limitations of lentiviral vectors include con-
strained packaging size (lentiviral particles are capable
of packaging only about 10kb of DNA efﬁciently) and
genomic silencing of integrated lentiviral transgenes, seen
both in vitro and in vivo (11,12). Ubiquitous chromatin
opening elements (UCOEs) have shown promise in main-
taining high levels of protein expression over extended
periods of time in in vitro transfection settings (13,14).
UCOEs have also been incorporated into lentiviral
vectors in order to prolong the expression of integrated
lentiviral transgenes in gene therapy settings (15,16). The
smallest element tested in these settings was a 2.0-kb
fragment of the HNRPA2B1/CBX3 locus (UCOE2.0);
however, given the size constraints of lentiviral packaging,
the use of this fragment signiﬁcantly limits the size of re-
combinant protein constructs that can be expressed.
Initially to address our own particular need to express a
natively glycosylated mammalian protein (Siderocalin) for
crystallographic studies, but also to more generally
address the limitations of current technologies, we report
the development of a generalizable protein expression
platform using lentiviral transduction of serum-free
adapted human 293 Freestyle (293-F) cells. This system,
designated ‘Daedalus’, is capable of producing large
quantities of readily puriﬁable, secreted recombinant
protein in a rapid manner. To enhance this system, we
have engineered a novel 0.7-kb UCOE fragment
(UCOE0.7) that, when incorporated into our lentiviral
vector, leads to the stable and enhanced expression of re-
combinant proteins of sizes approaching 70kDa. In
addition, we utilize a cis-linked ﬂuorescent reporter
(GFP) driven by an internal ribosome entry site (IRES)
that allows for rapid detection of transduced populations,
tracking relative protein expression levels, and obviates
time-consuming steps required for drug selection and iso-
lation of high expressing clones. Of the 14 proteins tested
with the Daedalus system, 12 were successfully expressed
at levels between 20 and 100mg/l in conventional
100ml-scale cultures and readily puriﬁed via a single chro-
matography step for use in multiple applications.
MATERIALS AND METHODS
Cell culture
293 Freestyle cells (Invitrogen) were grown in Freestyle
293 Expression media (Gibco) with shaking at 130rpm,
at 37 C and 8% CO2 in vented 125-ml shake ﬂasks
(Nalgene). CHO-S cells (Invitrogen) were grown in CHO
Expression media (Gibco) under the same conditions.
Lentiviral vector constructs
Lentiviral vector, pCVL-A (Figure 1A), was constructed
from pRRL-SIN-cPPT-PGK-GFP-WPRE (Addgene#
12252) by replacing the WPRE element with a WPRE-O
fragment (17), inserting two copies of a polyadenylation
(polyA) enhancer (18) into the 30 SIN LTR, and replacing
the native U5-polyA signal with the bovine growth
hormone (BGH) polyA signal sequence. The PGK
promoter was replaced with the spleen focus forming
virus (SFFV) promoter and the GFP sequence was
replaced with an IRES-eGFP sequence. The murine
Siderocalin sequence insert was isolated by PCR ampliﬁ-
cation of the expression construct used in E. coli with
primers including Xho I and Bam HI sites plus a
C-terminal Strep-tag II (SAWSHPQFEK) puriﬁcation
tag (19) and subcloned into the unique Xho I and Bam
HI restriction sites in the pCVL-A vector; the resulting
construct was designated pCVL-SFFV-muScn-
IRES-GFP. The UCOE fragment within the human
HNRPA2B1/CBX3 housekeeping gene locus (15) was
ampliﬁed from Nalm 6 genomic DNA [using primers:
UCOE50Nhe I—GCTAGCggatcctggtacctaaaacagc and
UCOE30Sal I—GTCGACagtcgcttcagcccg (anti-sense)],
TA-cloned and veriﬁed by sequencing and restriction
mapping. The 2.0-kb Acc 65/Xba I fragment of the
UCOE construct was blunted using Klenow (NEB) and
ligated into Mlu I digested/blunted pCVL-SFFV-muScn-
IRES-GFP upstream of the SFFV promoter. The forward
orientation of the UCOE was conﬁrmed by restriction
mapping; the derived construct was designated
pCVL-UCOE2.0-SFFV-muScn-IRES-GFP. A UCOE0.7
fragment (containing the CBX3 promoter of UCOE2.0)
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Mlu I (internal) and Eco RI, the SFFV promoter was
digested with Eco RI and Xho I and both fragments
were cloned into the pCVL-SFFV-muScn-IRES-GFP
vector (digested with Mlu I and Xho I) via a three-part
ligation reaction. The ﬁnal construct was designated
pCVL-UCOE0.7-SFFV-muScn-IRES-GFP. All subse-
quent candidate protein coding sequences were either
ampliﬁed with PCR primers (available upon request) con-
taining the required N-terminal signal peptide and a
C-terminal STREP-tag II sequence, or gene synthesized
(with codon utilization optimized for human expression)
and cloned into pCVL-UCOE0.7-SFFV-muScn-IRES-
GFP using the unique Xho I and Bam HI restriction
sites, replacing the muScn sequence. All restriction
enzymes were FastDigest, purchased from Fermentas.
Lentivirus production, concentration, titration and
transduction
Lentivirus was produced by transient transfection of 293T
(ATCC) cells using linear 25-kDa polyethyleneimine (PEI;
Polysciences). Brieﬂy, 4 10
6 cells were plated onto 10-cm
tissue culture plates. After 24h, 3mg of psPAX2, 1.5mgo f
pMD2G (Addgene plasmid #12260 and #12259, respect-
ively) and 6mg of lentiviral vector plasmid were mixed in
500ml diluent (5mM HEPES, 150mM NaCl, pH=7.05)
and 42ml of PEI (1mg/ml) and incubated for 15min. The
DNA/PEI complex was then added to the plate drop-wise.
Lentivirus was harvested 48h post-transfection,
concentrated 100-fold by low-speed centrifugation at
8000g for 18h and titered on human Nalm6 cells by
ﬂow cytometry and qPCR as previously described (20).
Transduction of the target cell line was carried out in
six-well plates containing 2 10
6 cells per well in 2ml of
growth media and 4mg/ml hexadimethrine bromide
(Polybrene; SIGMA). Titered virus was added to each
well at the designated multiplicity of infection (MOI;
four wells per condition) and the cells were incubated
with shaking (130rpm) at 37 C, in 8% CO2 for 4–6h.
The cells were then harvested, pooling the replicate
wells, and pelleted at low speed (1000g). Transduction
media was removed and replaced with 20ml fresh media
and cells were transferred to a 125-ml vented shake ﬂask
(Nalgene). Copy number was estimated using a previously
established genomic Q-PCR-based assay with comparison
to a housekeeping gene as well as control cell lines with a
deﬁned viral integration number based on Southern
blotting (21).
Protein expression, puriﬁcation and analysis
Transduced 293-F cells (at least 1 week post-transduction)
were seeded at 5 10
5 cells/ml in a 1-l vented shaker ﬂask
(Nalgene) in 100ml of 293 Expression media (Gibco).
Twenty-ﬁve milliliters of fresh media was added 2–3
days later, when cells reached densities of 2–3 10
6
cells/ml. The media was harvested after 5 days of total
incubation after measuring ﬁnal cell concentration and
viability. Culture supernatants were harvested by
low-speed centrifugation to remove cells and ﬁltered
through a 0.22-micron Centricon ultraﬁlter (Millipore).
NaCl was added to a ﬁnal concentration of 250mM and
the supernatants were concentrated to ﬁnal volumes of
 5ml using a Vivacell-100 centrifugal concentrator
(Sartorius Stedim). Recombinant proteins were separated
from media by size-exclusion chromatography (SEC) on a
Superdex 75 column (GE Healthsciences). Proteins were
transferred to PVDF-FL (Millipore) membranes for
western blot analysis with mouse anti-STREP primary
(IBA) and an anti-mouse-Alexa 680 (Molecular Probes)
secondary antibody, with results visualized using
Li-COR ﬂuorescent detection system (Odyssey).
Endotoxin levels were measured by the Pyrogene endo-
toxin detection system (Lonza) following the manufactur-
er’s protocols.
Crystallization and structure determination
Crystals of muScn were obtained by hanging drop vapor
diffusion at 25 C. The protein was concentrated to 12mg/
ml in standard phosphate-buffered saline (PBS) and mixed
1:1 v/v with a reservoir solution of 0.1M HEPES (pH 7.5),
10% v/v isopropanol and 20% w/w PEG 4000. Crystals
grew overnight and were cryoprotected in mother liquor
containing 10% v/v glycerol. Diffraction data were col-
lected at the Advanced Light Source 5.0.1 beamline
(Lawrence Berkeley National Laboratory). Data were
reduced with d*TREK (22). Initial structure factor
phase information was determined by molecular replace-
ment, using the program PHASER (23) as a part of the
CCP4i program suite (24). The structure of human
Figure 1. Maps of the lentiviral vectors used. Schematics are shown of
(A) lentiviral construct pCVL-A, (B) non-UCOE containing construct
pCVL-SFFV-muScn-IRES-GFP and (C) minimized UCOE containing
construct pCVL-UCOE0.7-SFFV-muScn-IRES-GFP. SP, signal
peptide; UCOE, ubiquitous chromatin opening element; SFFV, spleen
focus-forming virus enhancer/promoter; muScn, murine Siderocalin;
IRES, internal ribosome entry site.
PAGE 3 OF 11 Nucleic Acids Research, 2011,Vol.39, No. 21 e143Siderocalin (PDB code: 1X89, chain A) was used as a
search model. Model building and reﬁnement were
carried out using COOT (25) and refmac5 (26). The struc-
ture was submitted to the TLSMD server (27,28) and TLS
reﬁnement using a single group was applied to the ﬁnal
model. Structure validation was carried out with the
MolProbity server (29) and the RCSB ADIT server.
Functional assays
Bone marrow was harvested from C57BL/6 mice (Jackson
laboratories) and plated in a six-well dish at 1 10
6
cells/ml in 2ml of lymphocyte media (RPMI 1640
(Hyclone) supplemented with 10% FCS (Omega
Scientiﬁc), 5mM L-Alanyl-L-Glutamine (Mediatech),
100IU/ml penicillin–streptomycin (Mediatech) and
2mM b-mercaptoethanol (Gibco)) with 5ng/ml of
Daedalus IL-7 or commercial IL-7 (PeproTech). Media
with IL-7 was replaced at Day 3 and the resulting cell
populations were evaluated by ﬂuorescence-activated cell
sorting (FACS) at Day 5. Cells were stained with ﬂuores-
cein isothiocyanate (FITC) anti-mouse IgM (Jackson
Immuno Research) and PE anti-mouse B220 (BD) in
FACS staining buffer (PBS with 2.5% FCS) and
analyzed on an LSRII ﬂow cytometer (BD) and using
FlowJo software (Tree Star, Ashland, OR, USA).
Recombinant human LIF was tested for its ability to
maintain pluripotency of murine ES cells. Brieﬂy,
murine ES cells (AB1 ES cells kindly provided by Steve
Jones, University of Massachusetts) were plated on
irradiated feeder cells with either commercial human
LIF (Millipore) or Daedalus recombinant human LIF at
10ng/ml. Cells were split every 2 days with fresh media
and stained with APC anti-SSEA1 (BD) for analysis by
ﬂow cytometry.
RESULTS
Expression of murine Siderocalin using lentiviral
transduction of 293 Freestyle cells
The coding sequence of murine Siderocalin (muScn) was
cloned into the optimized lentiviral backbone pCVL-A
(Figure 1A) resulting in the construct pCVL-SFFV-
muScn-IRES-GFP (Figure 1B). The ability of this
lentiviral vector to transduce 293-F cells was compared
to the more commonly used CHO-S cell line. Compared
to CHO-S cells, the 293-F cells were more receptive to
viral transduction, at almost all multiplicities of infection
(MOI; 0.25–10), as measured by the higher mean ﬂuores-
cence intensity (MFI) of the GFP reporter. 293-F cells
were also more resistant to virus-mediated toxicity at the
highest MOI (10; Supplementary Figure S1).
293-F cells were transduced with the muScn lentivirus at
three different MOIs (Figure 2A) and GFP levels were
measured by ﬂow cytometry at 1 week post-transduction.
Essentially 100% of the cells were GFP positive
(Figure 2A) and muScn secretion was detectable even by
Coomassie blue staining of sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis (SDS–PAGE) analyses of
unconcentrated, 20ml samples of media supernatants
as soon as 7 days post-transduction (Figure 2B).
The identity of the protein was conﬁrmed by western
blot using an anti-STREP antibody (Figure 2B). The
IRES-GFP reporter proved to be a good surrogate for
protein expression as the increase in protein levels
correlated well with the increase in GFP levels at all
three MOIs. Effective protein yield in a 125-ml culture
was  13mg/l of fully glycosylated muScn; proper
folding was conﬁrmed by comparative reduced/
non-reduced SDS–PAGE and SEC.
Use of a novel, minimized UCOE to stabilize high-level
expression of muScn
Consistent with previous observations of silencing of lenti-
virus integrants in vitro and in vivo (11,12), long-term
culture (up to 1 month) of the transduced cells resulted
in a steady decline in GFP MFI and corresponding
protein levels (Figure 3A). In order to enhance protein
production and stably maintain expression levels for
extended periods, we incorporated two alternative
UCOE elements derived from the CpG island within the
human HNRPA2B1/CBX3 locus, either UCOE2.0 or
UCOE0.7. Expression levels from vectors incorporating
either element were comparable by initial GFP MFI
signal and were stable over extended periods of up to 1
month (Supplementary Figure S2). However, expression
levels, as measured by GPF MFI, from transductants
incorporating the truncated UCOE0.7 were substantially
enhanced relative to transductants lacking UCOEs (at
matched copy numbers of  8–10 copies) and were stable
over at least 1 month, consistent with resistance to
silencing (Figure 3B). The loss of GFP in the
transductants lacking the UCOE element was not due to
loss of the integrated gene as the viral copy number did
not vary signiﬁcantly over the 1-month period (data not
shown). It is possible to further enhance and prolong
protein expression by sorting for the highest GFP
positive (GFP
+) cells (Supplementary Figure S3). This
additional step, however, was not required and was
omitted for testing the expression/puriﬁcation of the
multiple subsequent proteins reported here.
Expression, puriﬁcation and crystallization of
293-expressed muScn
The goal of this effort was to produce large quantities of
muScn to support crystallographic studies, successful
completion of which would conﬁrm the proper folding
of the recombinant protein. At MOIs of 10–20,
pCVL-UCOE0.7-SFFV-muScn-IRES-GFP efﬁciently
transduced 293-F cells leading to a 100% GFP
+ popula-
tion, obviating any requirement for single-cell cloning or
sorting. A 200-ml culture incubated for 5 days yielded
 6mg of protein ( 37mg/l) after puriﬁcation by prepara-
tive SEC (Table 1 and Figure 4A). This yield was almost
3-fold higher than the yield obtained using the lentiviral
vector lacking UCOE. The protein obtained was
glycosylated and  99% pure (Figure 4A, inset). Final
culture density in this experiment was only about
3–4 10
6 cells per ml, compared to typical endpoint
densities of 8–10 10
6 cells per ml for CHO cell culture,
highlighting the efﬁciency of recombinant protein
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glycosylated, 293-F-expressed muScn was readily crystal-
lizable (Figure 4B) where non-glycosylated, recombinant
versions of muScn had previously been recalcitrant to
crystallization. The crystal structure (dmin=1.8A ˚ )o f
293-F-expressed muScn showed that the protein was
properly folded, with expected N-linked glycosylation
and intrachain disulﬁde bond formation readily apparent
(Table 2 and Figure 4C). The time required to go from
viral transduction to structure determination in this
example was only 18 days. Even though it had been suc-
cessfully crystallized with protein recombinantly expressed
from baculovirus and bacterial systems, human
Siderocalin (huScn) was also expressed (at a matched
copy number) using the same protocols for comparison.
The effective yield of huScn after puriﬁcation and
Figure 2. Transduction of 293-F cells at varying multiplicity of infection (MOI). (A) GFP MFI (mean ﬂuorescence intensity) is shown for three
different doses of pCVL-SFFV-muScn-IRES-GFP virus. (B) Analyses of expression of levels of muScn are shown; 20-ml aliquots from media
supernatants from each transduction were separated by SDS–PAGE and stained with Coomassie blue (left) or analyzed by western blot with an
anti-Strep II tag antibody (right).
Figure 3. Comparison of non-UCOE vs. UCOE0.7 containing constructs expressing murine Siderocalin. (A) GFP MFI measured over a 1-month
period for pCVL-SFFV-muScn-IRES-GFP. (B) GFP MFI, for the same period of time, for pCVL-UCOE0.7-SFFV-muScn-IRES-GFP. Cells were
matched for copy number and data are representative of three replicate experiments.
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Protein Signal peptide Residues in
construct
a
Mr
b (kDa) Type Glycosylation
sites
Peak yield
(mg/l)
muScn Native Met1–Asn180 22.4 Lipocalin 1 37.2
huScn Native Met1–Gly178 21.8 Lipocalin 1 46.7
huLcn15 Native Met1–Pro164 19.5 Lipocalin 0 101.1
huGlycodelin Native Met1–Phe162 20.1 Lipocalin 3 94.4
MICA (soluble) huScn Glu24–Ser274 32.7 Truncated integral membrane protein 8 82.3
MICAa3 huScn Thr81–Ser274 11.6 Truncated integral membrane protein 5 Did not express
CARMA-CARD huScn Asp2–Thr104 14.5 Cytoplasmic protein 0 21
4E10 huScn L: Glu23–Lys130 27.1 scFv 0 23.5
H: Gln21–Ser147
5B6 huScn L: Asp23–Arg113 27.5 scFv 0 Did not express
H: Gln21–Ser119
4E10 Igk L: Glu23–Lys130 26.9 scFv 0 29.4
H: Gln21–Ser147
Canine IL-3 huIL3 Arg24–Pro120 15.3 Cytokine 2 21.7
Canine G-CSF huIL3 Ala113–Pro286 20.0 Cytokine 1
c 34.8
Human IL-7 Native Met1–His177 18.7 Cytokine 3 12.3
Human LIF Native Met1–Phe202 21.0 Cytokine 7 48.3
aResidues for constructs with a non-native signal peptide correspond to sequence that was cloned downstream of the heterologous signal peptide.
bMolecular weights are listed according to the estimated molecular weight of the mature protein, lacking the signal peptide and any modiﬁcations.
cCanine G-CSF contains a single O-linked glycosylation site.
Figure 4. Puriﬁcation and crystallization of murine Siderocalin. (A) Preparative Superdex 75 SEC trace for muScn expressed using the optimized
lentiviral construct pCVL-UCOE0.7-SFFV-muScn-IRES-GFP. SDS–PAGE analysis of the peak fraction, before and after PNGase digestion, is
shown (inset). (B) Crystals obtained using the PEGs II Suite (Qiagen) sparse matrix screen, condition 63 [0.1M HEPES (pH 7.5), 10% v/v
isopropanol and 20% w/w PEG 4000]. (C) Crystal structure of muScn (red) superimposed on that of huScn (1X89 in black). Electron density
from a reﬁned Fo–Fc omit map contoured at 2.0 s showing the presence of the N-linked glycan and the intrachain disulﬁde bond.
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tions, a modest increase over muScn (Table 1).
Expression of other secreted proteins
In order to assess the general applicability of the Daedalus
system, a panel of secreted proteins was then tested for
expressibility: two additional human lipocalins, Lipocalin
15 (Lcn15) and glycodelin (Gd); the soluble ectodomain of
the human major histocompatibility complex class I
homolog MICA; the isolated, immunoglobulin-like a3
domain of MICA (MICAa3; Thr81-Ser274); and two
antibody single-chain Fv (scFv) constructs, derived from
either the anti-HIV antibody 4E10 or the anti-canine
CD28 antibody 5B6. All proteins were analyzed by ana-
lytical SEC (Supplementary Figure S5A–S5C) and SDS–
PAGE under reducing and non-reducing conditions
(Supplementary Figure S5D); yields were calculated
using the BCA protein assay (Table 1).
Lcn15 has, as yet, no known physiological function;
periplasmic expression of Lcn15 in E. coli had previously
produced only modest yields of  1mg of puriﬁed protein
per liter of culture. Gd can be isolated in multiple, func-
tionally relevant glycoforms (GdA, GdC, GdF and GdF)
from the female reproductive tract and seminal plasma
and primarily modulates sperm function (30,31). It had
been shown previously that HEK293 cells are capable of
producing functional GdA (32). Lcn15 and Gd were
cloned into the UCOE0.7-containing vector and expressed
and puriﬁed following the same methodology used for
Scn, resulting in yields of 94 and 103mg/l respectively, a
100-fold improvement in Lcn15 yield over periplasmic
bacterial expression.
MICA is a conditionally expressed self-antigen
recognized by the widely expressed, activating
immunoreceptor NKG2D (33). MICA, solubilized by
truncation prior to the transmembrane-spanning
segment at residue 274, had previously been produced as
a secreted protein in a baculovirus expression system (34),
yielding up to 7mg/l after harvesting 5 days post infection,
or by refolding denatured bacterial inclusion bodies
in vitro (35), an arduous and expensive (typically >$900
per milligram of puriﬁed protein) process that requires
considerable experimental ﬁnesse. Yields of puriﬁed
MICA range up to 1.1mg/l of input bacterial culture by
in vitro refolding. Refolded MICA, lacking N-linked
oligosaccharides, tended to aggregate over time.
Daedalus expression of MICA yielded up to 82mg/l of
puriﬁed, natively glycosylated protein that was stable in
solution over at least 3 months following puriﬁcation, a
74-fold improvement over the bacterial system. MICAa3,
a species that expressed poorly by every other technique
tried, was targeted to the secretion pathway by fusion with
a heterologous huScn signal peptide for testing in the
Daedalus system, but failed to yield measurable amounts
of protein.
Antibody scFv constructs recapitulate the binding
properties of the mature immunoglobulin (except
bivalent avidity); the 4E10 scFv was refolded from bacter-
ial inclusion bodies at yields up to 0.8mg per liter of
culture (36); Daedalus expression, using either huScn or
human Igk signal peptides, yielded up to 25mg/l of 4E10
scFv (Table 1), a 31-fold improvement, binding properties
of Daedalus-expressed and refolded 4E10 scFv were iden-
tical in surface plasmon resonance interaction analyses
(data not shown). The heavy and light variable regions
of the 4E10 were joined by a thrombin-cleavable linker
(sequence: LVPRGSGGGGLVPRGS), yielding pure
monobodies after cleavage; Daedalus-expressed scFv
cleaved as readily as refolded scFv, with thrombin added
directly to culture supernatants after concentration and
prior to puriﬁcation. A second scFv, based on antibody
5B6, was not puriﬁable from any conventional recombin-
ant system and was available only as sequence informa-
tion, as the parent hybridoma proved to be unstable.
Unfortunately, the 5B6 scFv also failed to produce meas-
urable yields in the Daedalus system.
Expression of functional, endotoxin-free, cytokines
Recombinant cytokines have become widely used in the
treatment of cancer (37), primary immunodeﬁciency
diseases (38), anemia and in conditioning patients
receiving hematopoietic stem cell transplants (HSCTs)
(39). However, recombinant cytokine therapeutics gener-
ally display limited plasma half-lives due to their innate
instability and rapid in vivo clearance, at least partially
accounted for by a lack of glycosylation, which can be
overcome by expression with native glycans, improving
efﬁcacy and stability (40,41).
Therefore, we also evaluated the capacity of the
Daedalus system to produce a panel of candidate cyto-
kines and assessed whether these recombinant proteins
exhibited normal levels of glycosylation and activity. We
evaluated human interleukin-7 (IL-7), human leukemic in-
hibitory factor (LIF), canine interleukin-3 (IL-3) and
Table 2. Data collection and reﬁnement statistics (molecular
replacement)
Data collection
Space group P212121
Lattice constants (A ˚ ) a=42.89 b=43.96 c=101.92
Resolution (A ˚ ) 42.89–1.8 (1.86–1.80)
Unique reﬂections 18574
Average redundancy 6.87 (7.09)
Completeness (%) 99.9 (100.0)
Rmerge (%) 4.6 (39.4)
I/ (I) 14.7 (3.5)
Reﬁnement
Rwork (%) 20.08
Rfree (%) 22.61
Number of atoms
Protein 1341
Ligand 50
Water 89
RMSD from ideal values
Bond lengths (A ˚ ) 0.015
Bond angles ( ) 1.50
Chiral volume (A ˚ 3) 0.07
Ramachandran
Most favored (%) 92.6
Additionally allowed (%) 6.1
Generously allowed (%) 0.0
Disallowed (%) 1.4
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IL-7 is essential for lymphocyte development, prolifer-
ation and activity; and therapeutically studied for
immune reconstitution following stem cell transplantation
and chemotherapy, as a vaccine adjuvant, and, more
recently, to treat sepsis (42). LIF is a multifunctional
growth factor that acts on several cell types. It is heav-
ily glycosylated (LIF has seven putative sites) and it
has been suggested that the glycosylation pattern, at
least of rat LIF, is essential for its function (43). LIF
has more recently become an important cytokine
for maintaining embryonic stem cells (ESCs) in an undif-
ferentiated state for their use in regenerative therapies (44)
as well as for developing induced pluripotent stem
cells (iPSCs) (45). Canine orthologs of IL-3 and G-CSF
have been useful for studying hematopoietic HSCT in
a canine model (46). Canine IL-3 displays low se-
quence identity to orthologs from other species (47)
necessitating the use of species-matched reagents in the
canine model.
Coding sequences for expression constructs for all four
cytokines were synthesized, with codon utilization
optimized for human expression, and inserted into the
UCOE0.7 containing vector; IL-7, LIF and IL-3 were ex-
pressed with their native signal peptide. G-CSF is en-
dogenously expressed as a pro-peptide that is further
processed to its mature form; for Daedalus expression,
the coding sequence for the mature protein was placed
downstream from the IL-3 signal peptide sequence that
scored higher than the native signal peptide by the
SignalP 3.0 algorithm (48). All four proteins were success-
fully expressed and puriﬁed with substantial yields
(Table 1), were glycosylated as seen by a shift in molecular
weight by SDS–PAGE (Supplementary Figure S5D) and
PNGase treatment of IL-7 and LIF (Supplementary
Figure S5E). All four proteins were also tested for endo-
toxin levels and were on average  10EU/mg and IL-7 and
LIF were tested for activity. IL-7 is known to promote
B-cell development in culture and was tested using
mouse bone marrow cells (49). The IL-7 produced using
the Daedalus system performed identically to commercial
IL-7 (Supplementary Figure S4A) in its ability to promote
and maintain B-cell (B220+IgM+) development of mouse
bone marrow cells in culture. The recombinant LIF was
also functionally tested in its ability to maintain mouse ES
cells in an undifferentiated state, as measured by mainten-
ance of the cell-surface marker SSEA1 in culture
(Supplementary Figure S4B) (50); there was no difference
compared to commercial LIF.
Expression of cytoplasmic proteins
One advantage of the Daedalus system is the ease with
which secreted proteins can be puriﬁed from the
serum-free supernatants of transduced cells. To determine
whether the Daedalus system could be adapted to
cytoplasmically targeted proteins, the expression of a cyto-
plasmic protein engineered with a heterologous signal
peptide (from huScn) was tested for efﬁcient secretion
into media supernatants. Caspase-recruitment domain
(CARD)-membrane-associated guanylate kinase protein
1 (CARMA1) is essential for lymphocyte activation and
immune function (51). The N-terminal CARD domain of
CARMA1 (CARMA-CARD) interacts with that of B-cell
lymphoma 10 (Bcl-10) and is essential for lymphocyte ac-
tivation via nuclear factor-kB (NF-kB) (52). CARMA-
CARD was successfully expressed as a cytoplasmically
targeted construct in E. coli (Bandanarayake et al., manu-
script in preparation) using a combination His6/maltose
binding protein puriﬁcation tag, fused to CARMA-
CARD through a tobacco etch virus (TEV) protease rec-
ognition sequence. Typical yields of CARMA-CARD
after tag cleavage and puriﬁcation from E. coli were
 10mg/l (Supplementary Figure S6B). Despite successful
expression, this recombinant form failed to crystallize
despite exhaustive screening. For testing Daedalus
expressibility, the huScn signal peptide sequence was
fused in-frame with the coding sequence of human
CARMA-CARD (Asp2-Thr104) and the fusion was
inserted into the pCVL-UCOE0.7-SFFV-IRES-GFP
vector backbone. A 100-ml culture of 293-F cells,
transduced with recombinant lentivirus produced as
described above, yielded 2.5mg (25mg/l) of protein after
ﬁnal SEC puriﬁcation ( 95% pure by PAGE).
Interestingly, SEC analysis of the Daedalus-expressed
CARMA-CARD protein showed a mixture of monomeric
and dimeric forms (Supplementary Figure S6A), whereas
the SEC analysis of bacterially expressed protein had
shown only the monomeric form (Supplementary Figure
S6B). The Daedalus CARMA-CARD homodimer was
isolated by preparative SEC and found to be a stable,
interchain disulﬁde-linked species as shown by compara-
tive reduced/non-reduced SDS–PAGE analysis
(Supplementary Figure S6C). Another CARD domain
protein, NOD1, also homodimerizes by forming a
strand-swapped dimer, stabilized by an adventitious
interchain disulﬁde when puriﬁed (53), suggesting that
the Daedalus system allows CARMA-CARD to access a
folding pathway not available in the cytoplasm of
bacteria. While possibly not physiological, the
CARMA-CARD interchain disulﬁde may also represent
an adventitious linkage, potentially in context of an analo-
gous strand-swapped dimer. Preliminary crystals of the
Daedalus-expressed CARMA-CARD dimer were
obtained, but require further optimization.
DISCUSSION
Lipocalin 2 (also known as Siderocalin, NGAL or 24p3) is
a bacteriostatic, innate immune system defense, secreted,
disulﬁde-containing glycoprotein that interferes with sid-
erophore mediated iron uptake in bacteria (54). huScn has
been successfully expressed recombinantly in both bacter-
ial ( 15mg/l) and baculovirus ( 5mg/l) expression
systems in order to support successful crystallographic
analyses (55,56). However, murine Siderocalin (muScn),
despite being successfully expressed in analogous bacterial
expression systems (yielding  15mg/l), proved refractory
to crystallization. Since the presence or absence of
N-glycans can affect crystallizability, an alternate expres-
sion system was sought that could produce readily
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milligram levels needed to support crystallization trials.
Using the Daedalus system, muScn was expressed at
decigram levels and puriﬁed (in a single SEC step) to
crystallizability within 18 days. Daedalus expression
levels for muScn ( 37mg/l) and huScn ( 46mg/l) dra-
matically exceeded yields from alternate systems.
One dozen additional expression targets were tested,
including additional lipocalins, truncated cell-surface
glycoproteins, an antibody scFv construct, cytokines and
cytoplasmic CARMA-CARD; 10 of these 12 targets were
successfully expressed at yields up to 100mg/ml,
demonstrating the wide potential utility and high potential
expression levels of the Daedalus platform, even when
limited to conventional shaking-ﬂask cell densities. The
293-F secretion system also ensured that only properly
folded and stable proteins were exported (57), adding an
additional internal quality control that could also be
applied to cytoplasmically targeted proteins by fusion
with heterologous signal peptide sequences (huScn).
Avoidance of bacteria during protein expression also
yields recombinant protein free of contaminating endo-
toxins without additional puriﬁcation steps.
Due to the packing limitations of lentiviruses, the
maximum construct that can be expressed in the
UCOE0.7 vector is  2.0kb, corresponding to Mrs about
70kDa. Further optimization of the vector may increase
this limit, but larger inserts may be packaged by deletion
of the IRES-GFP cassette, which, although useful for
rapid selection, is not necessary for viral or protein pro-
duction. This would increase the insert size by  1kb
which would enable the production of, for instance,
full-length antibody chains.
In summary, we have developed a rapid and scalable
expression system in 293-F cells by stabilizing the expres-
sion of recombinant proteins using a lentiviral delivery
vector. A key element of this invention was the incorpor-
ation of a minimized UCOE to prevent genomic silencing
of integrated expression cassettes. While previous studies
have utilized large UCOE elements (up to 8kb) within
plasmid constructs to obtain high expression clones in
mammalian cells (58,59), the Daedalus system exhibits a
number of signiﬁcant advantages including increased
speed, no requirement for producer cell selection or
cloning, and demonstrated capacity to generate a broad
range of functional proteins. The Daedalus system takes
advantage of both the more efﬁcient initial transduction
rates in 293-F cells and viral elements that permit sus-
tained high-level protein expression without a requirement
for cell cloning. The Daedalus platform is simple and
robust enough to enable academic labs to rapidly
produce recalcitrant proteins for research and may be
adaptable enough for therapeutic manufacturing and
other biotechnology applications.
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